Clinical trials
Phase 1/2 Myelodysplastic Syndromes trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asan Medical Center | 1 |
| Ascentage Pharma Group Inc. | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| Chinese PLA General Hospital | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
| CrystalGenomics, Inc. | 1 |
| Cyclacel Pharmaceuticals, Inc. | 1 |
| Diane George | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 23 |
| Leukemia, Myeloid, Acute | 18 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Lymphoma, Non-Hodgkin | 4 |
| Anemia, Aplastic | 3 |
| Hodgkin Disease | 3 |
| Leukemia | 3 |
| Lymphoma | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Multiple Myeloma | 2 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.